Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.WisTa Laboratories, a wholly owned subsidiary of TauRx Pharmaceuticals, has entered into a collaborative R&D agreement with Bayer Schering Pharma, which could redefine the way Alzheimer’s disease (AD) and related disorders are currently being diagnosed and treated.
Subscribe to our email newsletter
Through this collaboration, the two companies are expected to develop specific markers that will aid in the diagnostics and management of Tau-protein related AD using brain-imaging technology. The diagnostics they are jointly aiming to develop will have application in disease treatment and potentially disease prevention.
Under the agreement diagnostic products arising from the collaboration will be developed by Bayer Schering Pharma, whereas compounds with therapeutic potential will be developed by TauRx.
As part of the collaboration, TauRx is expected to utilise its proprietary technology platform of patented ligands, specialised Tau-directed assays and its animal models to optimise the development of ligands.
Claude Wischik, executive chairman of TauRx Pharma, said: “By bringing together our scientific expertise in Tau protein and BSP’s R&D capability in brain imaging diagnostics, we stand the best possible chance of bringing the combination of Tau-based diagnostics and therapeutics to patients as soon as possible.
“This collaboration marks another stage in the gradually increasing recognition by the field of the importance of the Tau protein pathology for both diagnostics and therapeutics in AD.”